Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIO-469 in Myelodysplastic Syndromes
NCT00113893Phase 2Completed
- Sponsor
- Scios Inc.
- Start
- May 2005
- Primary completion
- Dec 2007
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of talmapimod in myelodysplastic syndrome (MDS) (4 arms), sponsored by Scios Inc. Primary endpoint: Hematological Improvement - Erythroid at 16 weeks. Started May 2005; status: completed.
02
Drugs
talmapimod
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00113893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113893.